Plasma a?42 as biomarker of prodromal ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
URL permanente :
Titre :
Plasma a?42 as biomarker of prodromal alzheimer''s disease progression in patients with amnestic mild cognitive impairment: evidence from the pharmacog/e-adni study
Auteur(s) :
Albani, Diego [Auteur]
Marizzoni, Moira [Auteur]
Ferrari, Clarissa [Auteur]
Fusco, Federica [Auteur]
Boeri, Lucia [Auteur]
Raimondi, Ilaria [Auteur]
Jovicich, Jorge [Auteur]
Babiloni, Claudio [Auteur]
Soricelli, Andrea [Auteur]
Lizio, Roberta [Auteur]
Galluzzi, Samantha [Auteur]
Cavaliere, Libera [Auteur]
Didic, Mira [Auteur]
Schonknecht, Peter [Auteur]
Molinuevo, Jose Luis [Auteur]
Nobili, Flavio Mariano [Auteur]
Parnetti, Lucilla [Auteur]
Payoux, Pierre [Auteur]
Bocchio-Chiavetto, Luisella [Auteur]
Salvatore, Marco [Auteur]
Rossini, Paolo Maria [Auteur]
Tsolaki, Magda [Auteur]
Visser, Pieter Jelle [Auteur]
Richardson, Jill C. [Auteur]
Wiltfang, Jens [Auteur]
Bordet, Regis [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U1171
Blin, Olivier [Auteur]
Forloni, Gianluigi [Auteur]
Frisoni, Giovanni B. [Auteur]
Consortium, Pharmacog [Auteur]
Marizzoni, Moira [Auteur]
Ferrari, Clarissa [Auteur]
Fusco, Federica [Auteur]
Boeri, Lucia [Auteur]
Raimondi, Ilaria [Auteur]
Jovicich, Jorge [Auteur]
Babiloni, Claudio [Auteur]
Soricelli, Andrea [Auteur]
Lizio, Roberta [Auteur]
Galluzzi, Samantha [Auteur]
Cavaliere, Libera [Auteur]
Didic, Mira [Auteur]
Schonknecht, Peter [Auteur]
Molinuevo, Jose Luis [Auteur]
Nobili, Flavio Mariano [Auteur]
Parnetti, Lucilla [Auteur]
Payoux, Pierre [Auteur]
Bocchio-Chiavetto, Luisella [Auteur]
Salvatore, Marco [Auteur]
Rossini, Paolo Maria [Auteur]
Tsolaki, Magda [Auteur]
Visser, Pieter Jelle [Auteur]
Richardson, Jill C. [Auteur]
Wiltfang, Jens [Auteur]
Bordet, Regis [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U1171
Blin, Olivier [Auteur]
Forloni, Gianluigi [Auteur]
Frisoni, Giovanni B. [Auteur]
Consortium, Pharmacog [Auteur]
Titre de la revue :
Journal of Alzheimer's disease . JAD
Nom court de la revue :
J. Alzheimers Dis.
Date de publication :
2018-08-20
ISSN :
1875-8908
Mot(s)-clé(s) en anglais :
amyloid-beta peptide
clinical trial
clusterin
PharmaCog project
prodromal Alzheimer''s disease
Amnesic mild cognitive impairment
biomarkers
clinical trial
clusterin
PharmaCog project
prodromal Alzheimer''s disease
Amnesic mild cognitive impairment
biomarkers
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
It is an open issue whether blood biomarkers serve to diagnose Alzheimer's disease (AD) or monitor its progression over time from prodromal stages. Here, we addressed this question starting from data of the European FP7 ...
Lire la suite >It is an open issue whether blood biomarkers serve to diagnose Alzheimer's disease (AD) or monitor its progression over time from prodromal stages. Here, we addressed this question starting from data of the European FP7 IMI-PharmaCog/E-ADNI longitudinal study in amnesic mild cognitive impairment (aMCI) patients including biological, clinical, neuropsychological (e.g., ADAS-Cog13), neuroimaging, and electroencephalographic measures. PharmaCog/E-ADNI patients were classified as "positive" (i.e., "prodromal AD" n = 76) or "negative" (n = 52) based on a diagnostic cut-off of Aβ42/P-tau in cerebrospinal fluid as well as APOE ε 4 genotype. Blood was sampled at baseline and at two follow-ups (12 and 18 months), when plasma amyloid peptide 42 and 40 (Aβ42, Aβ40) and apolipoprotein J (clusterin, CLU) were assessed. Linear Mixed Models found no significant differences in plasma molecules between the "positive" (i.e., prodromal AD) and "negative" groups at baseline. In contrast, plasma Aβ42 showed a greater reduction over time in the prodromal AD than the "negative" aMCI group (p = 0.048), while CLU and Aβ40 increased, but similarly in the two groups. Furthermore, plasma Aβ42 correlated with the ADAS-Cog13 score both in aMCI patients as a whole and the prodromal AD group alone. Finally, CLU correlated with the ADAS-Cog13 only in the whole aMCI group, and no association with ADAS-Cog13 was found for Aβ40. In conclusion, plasma Aβ42 showed disease progression-related features in aMCI patients with prodromal AD.Lire moins >
Lire la suite >It is an open issue whether blood biomarkers serve to diagnose Alzheimer's disease (AD) or monitor its progression over time from prodromal stages. Here, we addressed this question starting from data of the European FP7 IMI-PharmaCog/E-ADNI longitudinal study in amnesic mild cognitive impairment (aMCI) patients including biological, clinical, neuropsychological (e.g., ADAS-Cog13), neuroimaging, and electroencephalographic measures. PharmaCog/E-ADNI patients were classified as "positive" (i.e., "prodromal AD" n = 76) or "negative" (n = 52) based on a diagnostic cut-off of Aβ42/P-tau in cerebrospinal fluid as well as APOE ε 4 genotype. Blood was sampled at baseline and at two follow-ups (12 and 18 months), when plasma amyloid peptide 42 and 40 (Aβ42, Aβ40) and apolipoprotein J (clusterin, CLU) were assessed. Linear Mixed Models found no significant differences in plasma molecules between the "positive" (i.e., prodromal AD) and "negative" groups at baseline. In contrast, plasma Aβ42 showed a greater reduction over time in the prodromal AD than the "negative" aMCI group (p = 0.048), while CLU and Aβ40 increased, but similarly in the two groups. Furthermore, plasma Aβ42 correlated with the ADAS-Cog13 score both in aMCI patients as a whole and the prodromal AD group alone. Finally, CLU correlated with the ADAS-Cog13 only in the whole aMCI group, and no association with ADAS-Cog13 was found for Aβ40. In conclusion, plasma Aβ42 showed disease progression-related features in aMCI patients with prodromal AD.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
CNRS
Inserm
Université de Lille
CNRS
Inserm
Université de Lille
Collections :
Équipe(s) de recherche :
Troubles cognitifs dégénératifs et vasculaires
Date de dépôt :
2019-11-27T14:31:47Z